Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorMutlu, Pelin
dc.contributor.authorAzarkan, Serap Yalcin
dc.contributor.authorPourianazar, Negar Taghavi
dc.contributor.authorYucel, Meral
dc.contributor.authorGunduz, Ufuk
dc.date.accessioned2019-11-24T20:57:55Z
dc.date.available2019-11-24T20:57:55Z
dc.date.issued2018
dc.identifier.issn1611-2156
dc.identifier.urihttps://dx.doi.org/10.17179/excli2018-1129
dc.identifier.urihttps://hdl.handle.net/20.500.12513/2908
dc.descriptionWOS: 000431691800003en_US
dc.descriptionPubMed ID: 29805346en_US
dc.description.abstractActivation of the Wnt signaling in some types of cancer and its relation with chemotherapy resistance is a very interesting issue that has been emphasized in recent years. Although, it is known that increase in the activity of beta-catenin is important in blast transformation and drug resistance, the underlying mechanisms are still unclear. In this study, changes in the expression levels of 186 genes that are thought to be important in drug resistance and Wnt signaling pathways were determined by using qPCR method in doxorubicin-sensitive and -resistant HeLa and K562 cell lines. It has been observed that the genes involved in the Wnt signaling pathways are involved in more changes in HeLa/Dox cells (36 genes) than in the K562/Dox cells (17 genes). Genes important for the development of cancer resistance have been found to be significantly different in expression levels of 18 genes in HeLa/Dox cells and 20 genes in K562/Dox cells. In both cell lines, the expression of ABCB1 gene was significantly increased to 160 and 103 fold, respectively. However, despite the resistance to same drug in HeLa and K562 cell lines, it appears that the expression levels of different oncogenes and genes involved in Wnt signaling pathways have been altered. It has been found that although resistance develops to the same drug in both cell lines, the expression levels of different genes have changed. If functional analysis of these genes is performed on patient population groups, these molecules may become candidates for novel therapeutic target molecules.en_US
dc.description.sponsorshipTUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [214S634]en_US
dc.description.sponsorshipThis work was supported by TUBITAK 3001 project (Project No: 214S634).en_US
dc.language.isoengen_US
dc.publisherEXCLI JOURNAL MANAGING OFFICEen_US
dc.relation.isversionof10.17179/excli2018-1129en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectWnt signaling pathwayen_US
dc.subjectdrug resistanceen_US
dc.subjectcervical canceren_US
dc.subjectchronic myelogenous leukemiaen_US
dc.subjectgene expressionen_US
dc.titleDETERMINATION OF THE RELATIONSHIP BETWEEN DOXORUBICIN RESISTANCE AND WNT SIGNALING PATHWAY IN HELA AND K562 CELL LINESen_US
dc.typearticleen_US
dc.relation.journalEXCLI JOURNALen_US
dc.contributor.departmentKırşehir Ahi Evran Üniversitesi, Fen-Edebiyat Fakültesi, Moleküler Biyoloji ve Genetik Bölümüen_US
dc.identifier.volume17en_US
dc.identifier.startpage386en_US
dc.identifier.endpage398en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster